Journal of the National Cancer Institute · Nov 19, 2026

Integrating genetic and lung tissue proteomics data to identify susceptibility proteins for lung cancer

By Xu S, Shi J, Shu XO et al.

BACKGROUND: Proteins directly impact disease development and act as drug targets. We integrated genetic and lung tissue proteomic data to identify lung cancer susceptibility proteins and evaluated them as candidate drug targets. METHOD: We profiled the proteome and genome in 200 non-neoplastic lung tissue samples and constructed genetic models to predict protein abundance. These models were applied to genome-wide association study (GWAS) data of 55,174 lung cancer cases and 1,294,174 controls to evaluate associations between predicted abundance and lung cancer risk overall and by major histological subtypes. Independent lung tissue proteomic data was used for cross-dataset evaluation, followed by colocalization and summary-data-based Mendelian randomization. Prioritized proteins were cross-referenced against drug databases. RESULTS: We identified 29 lung cancer risk-associated proteins at a false discovery rate < 5%, including 25 for overall lung cancer, two (AQP3 and IL18) specific to adenocarcinoma, and two (HMGN2 and HLA-DMB) specific to squamous cell carcinoma. Genes encoding 15 proteins are located > 2Mb away from known GWAS risk loci. Among the remaining 14 proteins at known risk loci, five (EPHX2, CLDN18, PSMD5, ARHGAP27, and CYP2S1) showed associations independent of proximal lead variant. Of the 29 proteins, eight were predicted and six were significant in independent data. DSP, IL18 and TYMP proteins demonstrated both reproducible and potential causal evidence and are targeted by six drugs that are FDA-approved or in phase III trials. CONCLUSION: Our study identified novel lung cancer susceptibility proteins and potential therapeutic targets, offering insights into lung cancer biology and informing future translational research.

doi.org/10.1093/jnci/djag424Open accessPubMed 43055353Biomarkers

AgingResearch.News